EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution

Meletios A Dimopoulos iD, Ioannis Ntanasis-Stathopoulos iD, Despina Fotiou, Foteini Theodorakakou iD, Eirini Solia, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Erasmia Psimenou, Stavroula Giannouli, Nikolaos Kanellias, Vassilis Koutoulidis, Maria Roussou und 6 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Meletios A Dimopoulos und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic advances during the last two decades have rendered multiple myeloma a chronic disease and, thus, it is important to identify patient subgroups which may have extremely favorable outcomes and optimize their treatment. The current study aimed to evaluate the clinical and disease characteristics of patients with very long follow‐up (minimum 15 years), to identify those with very long survival (> 15 years) and those with very long disease remissions (> 15 years) after frontline treatment diagnosed at a single center from 1994 to 2009. Among 323 consecutive, unselected patients, the calculated 15‐year and 20‐year cumulative survival rates were 18% and 14%, respectively. Forty‐nine survived for more than 15 years. Furthermore, the calculated 15‐year and 20‐year cumulative PFS rates for the 323 patients were 9% and 7%, respectively; 25 (8%) patients were identified as long‐term progression‐free survivors. Younger age (≤ 65 years), good performance status (ECOG PS 0–1), low/intermediate risk stratification (ISS 1 or 2), absence of adverse cytogenetic abnormalities, autologous transplantation and achievement of CR to initial therapy were significantly associated with prolonged PFS. Importantly, all patients who were in complete response with negative minimal residual disease at 15 years remained at the same disease status at last follow‐up. In conclusion, among patients treated with either conventional chemotherapy or with first‐generation novel agents (thalidomide, bortezomib, or lenalidomide), about 15% were long‐term survivors and 8% remained in long‐term remission for more than 15 years without maintenance treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansAgedMiddle AgedMaleFemaleAdultProgression-Free SurvivalFollow-Up StudiesAged, 80 and overSurvival RateRetrospective StudiesDisease-Free SurvivalTransplantation, AutologousNeoplasm, Residual

Stichwörter der Autor:innen

chemotherapyfunctional curemultiple myelomanovel agentsoverall survivalprogression‐free survival

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Medicine, Korea University, Seoul, South Korea.
  • Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • First Department of Radiology, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Meletios A Dimopoulos, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis

Zitieren

APA

Dimopoulos, M. A., Ntanasis-Stathopoulos, I., Fotiou, D., Theodorakakou, F., Solia, E., Spiliopoulou, V., Malandrakis, P., Psimenou, E., Giannouli, S., Kanellias, N., Koutoulidis, V., Roussou, M., Andrikopoulou, A., Migkou, M., Eleutherakis-Papaiakovou, E., Gavriatopoulou, M., Terpos, E., & Kastritis, E. (2025). Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution. American Journal of Hematology. https://doi.org/10.1002/ajh.70012

Vancouver

Dimopoulos MA, Ntanasis-Stathopoulos I, Fotiou D, Theodorakakou F, Solia E, Spiliopoulou V, et al. Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution. American Journal of Hematology. 2025. doi:10.1002/ajh.70012

BibTeX
@article{Dimopoulos2025,
  author = {Dimopoulos, Meletios A and Ntanasis-Stathopoulos, Ioannis and Fotiou, Despina and Theodorakakou, Foteini and Solia, Eirini and Spiliopoulou, Vasiliki and Malandrakis, Panagiotis and Psimenou, Erasmia and Giannouli, Stavroula and Kanellias, Nikolaos and Koutoulidis, Vassilis and Roussou, Maria and Andrikopoulou, Angeliki and Migkou, Magdalini and Eleutherakis-Papaiakovou, Evangelos and Gavriatopoulou, Maria and Terpos, Evangelos and Kastritis, Efstathios},
  title = {Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.70012}
}
Kostenlos starten →